Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -25.29% is 75% above its 5-year average of -101.26%, near the high end of its 5-year range (-283.50%–-23.16%).
As of the fiscal period ended Tuesday, June 30, 2026. 43.70% above its 12-month average of -44.91%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -25.29%.
RETURN ON EQUITY (ROE)
-25.29%
RETURN ON EQUITY (ROE) AVG TTM
-44.91%
RETURN ON EQUITY (ROE) AVG 3Y
-43.76%
RETURN ON EQUITY (ROE) AVG 5Y
-101.26%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+43.70%
CURRENT VS 3Y AVG
+42.21%
CURRENT VS 5Y AVG
+75.03%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.78%
median of 740 covered companies
CURRENT VS SECTOR MEDIAN
+39.48%
vs the sector median at left
Praxis Precision Medicines, Inc.
Market Cap
$7.69B
Return on Equity (ROE)
-25.29%
TTM Avg
-44.91%
3Y Avg
-43.76%
5Y Avg
-101.26%
Market Cap
$7.61B
Return on Equity (ROE)
N/A
TTM Avg
277.25%
3Y Avg
262.80%
5Y Avg
141.77%
Market Cap
$7.61B
Return on Equity (ROE)
11.88%
TTM Avg
7.39%
3Y Avg
4.04%
5Y Avg
2.40%
Market Cap
$7.58B
Return on Equity (ROE)
31.68%
TTM Avg
-71.21%
3Y Avg
-55.91%
5Y Avg
-55.91%
Market Cap
$7.95B
Return on Equity (ROE)
73.08%
TTM Avg
39.77%
3Y Avg
-73.65%
5Y Avg
-82.53%
Market Cap
$7.93B
Return on Equity (ROE)
17.77%
TTM Avg
-40.95%
3Y Avg
-11.78%
5Y Avg
-8.64%
Market Cap
$7.32B
Return on Equity (ROE)
-128.44%
TTM Avg
-77.53%
3Y Avg
-74.21%
5Y Avg
-60.06%
Market Cap
$7.00B
Return on Equity (ROE)
3.66%
TTM Avg
19.17%
3Y Avg
13.19%
5Y Avg
6.34%
Market Cap
$8.37B
Return on Equity (ROE)
26.84%
TTM Avg
-21.41%
3Y Avg
-36.14%
5Y Avg
-25.75%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Praxis Precision Medicines, Inc. (PRAX) | $7.69B | -25.29% | -44.91% | -43.76% | -101.26% |
| Cytokinetics, Incorporated (CYTK)vs › | $7.61B | N/A | 277.25% | 262.80% | 141.77% |
| HealthEquity, Inc. (HQY)vs › | $7.61B | 11.88% | 7.39% | 4.04% | 2.40% |
| Hinge Health, Inc. (HNGE)vs › | $7.58B | 31.68% | -71.21% | -55.91% | -55.91% |
| TG Therapeutics, Inc. (TGTX)vs › | $7.95B | 73.08% | 39.77% | -73.65% | -82.53% |
| Caris Life Sciences, Inc. (CAI)vs › | $7.93B | 17.77% | -40.95% | -11.78% | -8.64% |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.32B | -128.44% | -77.53% | -74.21% | -60.06% |
| Alkermes plc (ALKS)vs › | $7.00B | 3.66% | 19.17% | 13.19% | 6.34% |
| Oscar Health, Inc. (OSCR)vs › | $8.37B | 26.84% | -21.41% | -36.14% | -25.75% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.59B | -19.85% | -23.25% | -28.82% | -25.53% |
ROE
-25.3%
ROA
-24.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -25.29% |
| 2026-03-31 | -23.16% |
| 2025-12-31 | -34.54% |
| 2025-09-30 | -79.49% |
| 2025-06-30 | -62.10% |
| 2025-03-31 | -48.40% |
| 2024-12-31 | -41.04% |
| 2024-09-30 | -39.46% |
| 2024-06-30 | -29.53% |
| 2024-03-31 | -54.59% |
| 2023-12-31 | -176.95% |
| 2023-09-30 | -158.57% |
| 2023-06-30 | -148.53% |
| 2023-03-31 | -283.50% |
| 2022-12-31 | -281.22% |
| 2022-09-30 | -220.08% |
| 2022-06-30 | -167.21% |
| 2022-03-31 | -109.10% |
| 2021-12-31 | -66.61% |
| 2021-09-30 | -45.34% |
| 2021-06-30 | -31.67% |
| 2021-03-31 | -30.46% |
| 2020-12-31 | -21.51% |
| 2019-12-31 | -93.97% |
